25 June 2025

N4 Pharma plc

("N4 Pharma" or the "Company")

N4 Pharma Insight Event for Retail Investors

N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to announce that it will host an Investor Insight Event for retail investors on Monday, 14 July 2025 at the Royal College of Surgeons, 38-43 Lincoln's Inn Fields, London, WC2A 3PE from 10.00 am until 12.00 pm.

During the event, Nigel Theobald, Chief Executive Officer, will provide a strategic update on the Company's ongoing development of Nuvec® as a delivery system for RNA therapeutics. He will be joined by members of the Senior Leadership Team, including:

·      Mark Edbrooke, Head of Strategy, presenting on The RNA Therapeutics Revolution

·      Dr Fiona McLaughlin, Head of Research and Development, presenting on Established Delivery Platforms and the Key Benefits of Nuvec®

The event will include a Q&A session, offering investors the opportunity to engage directly with the executive team. This will be followed by a networking lunch, where attendees can meet other members of the Board and senior management.

The event is free to attend and open to all existing and prospective shareholders.

To register for the event, please contact [email protected]

A recording of the presentation will be made available on the Company's website following the event at: https://www.n4pharma.com/.

- Ends -

For more information please contact:

About N4 Pharma

N4 Pharma is a pre-clinical biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.

RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.

N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.

N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for IBD which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.

For further information on the Company visit www.n4pharma.com or sign up at https://investors.n4pharma.com/auth/signup.